

Desmond J Fitzgerald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11368962/publications.pdf>

Version: 2024-02-01

38
papers

5,138
citations

236925

25
h-index

330143

37
g-index

38
all docs

38
docs citations

38
times ranked

4616
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet Activation in Unstable Coronary Disease. <i>New England Journal of Medicine</i> , 1986, 315, 983-989.	27.0	1,138
2	Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. <i>Blood</i> , 2004, 103, 2096-2104.	1.4	725
3	Ticlopidine and Clopidogrel. <i>Circulation</i> , 1999, 100, 1667-1672.	1.6	461
4	Cyclooxygenase-1 and -2-Dependent Prostacyclin Formation in Patients With Atherosclerosis. <i>Circulation</i> , 2000, 102, 840-845.	1.6	368
5	Oxidative Damage of Cardiomyocytes Is Limited by Extracellular Regulated Kinases 1/2-mediated Induction of Cyclooxygenase-2. <i>Journal of Biological Chemistry</i> , 1999, 274, 5038-5046.	3.4	336
6	Effect of Enteric Coating on Antiplatelet Activity of Low-Dose Aspirin in Healthy Volunteers. <i>Stroke</i> , 2006, 37, 2153-2158.	2.0	206
7	Platelet Response to Low-Dose Enteric-Coated Aspirin in Patients With Stable Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1258-1263.	2.8	205
8	Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease. <i>Circulation</i> , 2007, 115, 2196-2207.	1.6	191
9	Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. <i>Journal of Clinical Investigation</i> , 2001, 108, 585-590.	8.2	171
10	Identification of the phosphotyrosine proteome from thrombin activated platelets. <i>Proteomics</i> , 2002, 2, 642-648.	2.2	165
11	Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2000, 36, 1514-1519.	2.8	135
12	Cyclooxygenase Isoforms and Platelet Vessel Wall Interactions in the Apolipoprotein E Knockout Mouse Model of Atherosclerosis. <i>Circulation</i> , 2003, 108, 3017-3023.	1.6	129
13	Moderation of the platelet releasate response by aspirin. <i>Blood</i> , 2007, 109, 4786-4792.	1.4	120
14	Intravascular Thrombosis After Hypoxia-Induced Pulmonary Hypertension. <i>Circulation</i> , 2004, 110, 2701-2707.	1.6	92
15	Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. <i>Blood</i> , 2010, 116, 4646-4656.	1.4	90
16	Vascular endothelial cell growth factor (VEGF) induces cyclooxygenase (COX)-dependent proliferation of endothelial cells (EC) via the VEGFR2 receptor. <i>FASEB Journal</i> , 2001, 15, 1667-1669.	0.5	64
17	Canonical Wnt signaling negatively regulates platelet function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19836-19841.	7.1	61
18	Aspirin and coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1175-1181.	3.4	60

#	ARTICLE	IF	CITATIONS
19	Correlation of probiotic <i>Lactobacillus salivarius</i> growth phase with its cell wall-associated proteome. <i>FEMS Microbiology Letters</i> , 2005, 252, 153-159.	1.8	50
20	Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse. <i>Atherosclerosis</i> , 2009, 202, 84-91.	0.8	46
21	Aspirin and Clopidogrel Resistance. <i>Hematology American Society of Hematology Education Program</i> , 2007, 2007, 114-120.	2.5	38
22	Historical Lessons in Translational Medicine. <i>Circulation Research</i> , 2013, 112, 174-194.	4.5	38
23	Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of β_1 and β_2 adrenergic receptors. <i>British Journal of Haematology</i> , 2003, 121, 157-164.	2.5	34
24	Ilprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. <i>European Heart Journal</i> , 2006, 27, 1251-1256.	2.2	33
25	Optimal suppression of thromboxane α_2 formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. <i>Journal of the American College of Cardiology</i> , 2004, 43, 526-531.	2.8	30
26	Application of Proteomics to the Study of Platelet Regulatory Mechanisms. <i>Trends in Cardiovascular Medicine</i> , 2004, 14, 207-220.	4.9	18
27	Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H532-H536.	3.2	18
28	Platelet activation in the pathogenesis of unstable angina: Importance in determining the response to plasminogen activators. <i>American Journal of Cardiology</i> , 1991, 68, B51-B57.	1.6	17
29	Growth Arrest Specific Gene (GAS) 6 Modulates Platelet Thrombus Formation and Vascular Wall Homeostasis and Represents an Attractive Drug Target. <i>Current Pharmaceutical Design</i> , 2007, 13, 2656-2661.	1.9	16
30	Abciximab pharmacodynamic model with neural networks used to integrate sources of patient variability. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 60-69.	4.7	14
31	Reduced fetal exposure to aspirin using a novel controlled-release preparation in normotensive and hypertensive pregnancies. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 1998, 105, 732-738.	2.3	12
32	Isolation of the Platelet Releasate. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 7, 307-312.		12
33	Relation Between Aspirin Dose, All-Cause Mortality, and Bleeding in Patients With Recent Cerebrovascular or Coronary Ischemic Events (from the BRAVO Trial). <i>American Journal of Cardiology</i> , 2008, 102, 1285-1290.	1.6	12
34	A Val193Met mutation in GPIIIa results in a GPIIb/IIIa receptor with a constitutively high affinity for a small ligand. <i>British Journal of Haematology</i> , 2001, 115, 131-139.	2.5	11
35	Lack of Bioequivalence Among Low-dose, Enteric-coated Aspirin Preparations. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1047-1051.	4.7	9
36	Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes: Where Are We Now?. <i>Seminars in Vascular Medicine</i> , 2003, 03, 385-390.	2.1	7

#	ARTICLE	IF	CITATIONS
37	Drug Insight: aspirin resistance—fact or fashion?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007, 4, E1-E1.	3.3	4
38	Aspirin Resistance and Atherothrombotic Disease. <i>Journal of the American College of Cardiology</i> , 2006, 48, 846-847.	2.8	2